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Abstract
Background: The effectiveness of mechanical thrombectomy (MT) in cancer-related stroke (CRS) is largely
unknown. This study aims to investigate the clinical and radiological outcomes of MT in CRS patients. We also
explored the factors that independently affect functional outcomes of patients with CRS after MT.
Methods: We retrospectively reviewed 341 patients who underwent MT after acute ischemic stroke onset between
May 2014 and May 2020. We classified the patients into CRS (n = 34) and control (n = 307) groups and compared
their clinical details. Among CRS patients, we analyzed the groups with and without good outcomes (3-months
modified Rankin scale [mRS] score 0, 1, 2). Multivariate analysis was performed to investigate the independent
predictors of unfavorable outcomes in patients with CRS after MT.
Results: A total of 341 acute ischemic stroke patients received MT, of whom 34 (9.9%) had CRS. Although the
baseline National institute of health stroke scale (NIHSS) score and the rate of successful recanalization was not
significantly different between CRS patients and control group, CRS patients showed more any cerebral
hemorrhage after MT (41.2% vs. controls 23.8%, p = 0.037) and unfavorable functional outcome at 3 months (CRS
patients median 3-month mRS score 4, interquartile range [IQR] 2 to 5.25 vs. controls median 3-month mRS score 3,
IQR 1 to 4, [p = 0.026]). In the patients with CRS, elevated serum D-dimer level and higher baseline NIHSS score
were independently associated with unfavorable functional outcome at 3 months (adjusted odds ratio [aOR]: 1.524,
95% confidence interval [CI]: 1.043–2.226; aOR: 1.264, 95% CI: 1.010–1.582, respectively).
Conclusions: MT is an appropriate therapeutic treatment for revascularization in CRS patients. However, elevated
serum D-dimer levels and higher baseline NIHSS scores were independent predictors of unfavorable outcome.
Further research is warranted to evaluate the significance of these predictors.
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Introduction
Cerebrovascular disease affects around 15% of all pa-
tients with malignancy throughout their life. Patients
with cancer frequently experience acute ischemic stroke
(AIS) [1]. The pathophysiology of AIS in cancer is vary.
Among these, cancer-related stroke (CRS) by intravascu-
lar coagulopathy by tumor-cell derived cytokines or mi-
croparticles, is of particular concern [2, 3]. Serum D-
dimer level is often high (> 1.11 μg/mL) and multiple le-
sions in various vascular territories are associated with
CRS [4, 5]. With the advancement of anti-cancer ther-
apy, the survival period has been prolonged; therefore,
CRS and the need for thrombolysis has increased [6].
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However, due to conditions such as thrombocytopenia,
or recent surgery, patients with CRS are often excluded
for intravenous recombinant tissue plasminogen activa-
tor (rtPA) administration [7–9]. Therefore, mechanical
thrombectomy (MT) for occluded large vessels can be a
particularly important treatment option for CRS patients
[10, 11]. However, although there have been earlier stud-
ies showing the overall outcomes of MT in patients with
CRS [12–17], the effectiveness of MT on CRS remains
controversial as patients with active cancer were ex-
cluded from previous important clinical trials [18–21].
To the best of our knowledge, there have not been any
studies investigating the independent factors associated
with the functional outcomes of CRS after MT. There-
fore, this study aimed to investigate the effectiveness of
MT in CRS patients. We also explored the factors that




We retrospectively reviewed the medical records of all
372 consecutive patients with AIS who received MT in
the Seoul National University Hospital (SNUH) between
May 2014 and May 2020. The following patients were
excluded: MT performed > 24 h after onset; patients with
active hematologic malignancies, intracranial neoplasm,
or central nervous system metastasis; and patients whose
clinical follow-up with a modified Rankin scale (mRS)
score at 3-month was unavailable. The final study popu-
lation was 341. Patients who received MT were divided
into two groups: the CRS group and the control. CRS
was defined as a cryptogenic ischemic stroke occurring
in active cancer patients who had elevated D-dimer
levels and/or multiple cerebral territory involvement on
diffusion weighted imaging. Active cancer patients re-
ferred to those who were diagnosed and currently
undergoing or refusing treatment for malignancy. Pa-
tients diagnosed during hospitalization for stroke were
also included. The involvement of multiple cerebral ter-
ritories was defined as the presence of multiple ischemic
lesions in the unilateral anterior and posterior circula-
tion, bilateral anterior circulation, or bilateral anterior
and posterior circulation [22].
This study was approved by the institutional review
board (IRB number: 1009–062-332) of SNUH. Informed
consent was waived by the IRB due to the retrospective
nature of the study.
Clinical assessment
Age, sex, pre-stroke mRS scores, baseline National Insti-
tute of Health Stroke Scale (NIHSS) scores, conventional
vascular risk factors (history of hypertension, diabetes
mellitus, dyslipidemia, atrial fibrillation, and previous
ischemic stroke or transient ischemia attack, coronary
artery disease, and smoking status), laboratory findings
(hemoglobin level, White blood cells [WBC] count,
platelet counts, prothrombin time, total cholesterol level,
level of high-density lipoprotein cholesterol [HDL-C],
level of low-density lipoprotein cholesterol [LDL-C], and
level of C-reactive protein [CRP]), whether the stroke
onset is in hospital, occlusion site where the MT was
performed, and the status of receiving intravenous rtPA
administration of each subject were collected from the
database of SNUH’s stroke registry. The occluded loca-
tion was classified into M1 and M2 of middle cerebral
artery (MCA), internal carotid artery (ICA), and poster-
ior circulation (posterior cerebral artery [PCA] and basi-
lar artery [BA]). Regarding the time variable associated
with MT, onset-to-puncture time and puncture-to-
reperfusion time were gathered. When the onset time
was unclear, the last normal time was used as the refer-
ence and the reperfusion time was defined as the first re-
perfusion with mTICI ≥2a.
The decision to perform MT was determined based on
multimodal computed tomography (CT) such as non-
contrast CT, CT angiography, and perfusion CT. Mag-
netic resonance image (MRI) was additionally used in
some cases. Intravenous rtPA was used within 4.5 h after
symptom onset if the patients met the relevant criteria.
MT was performed using stent retrievers or a forced
suction system selected, depending on the preference of
the neurointerventionalists. Unless there was a specific
contraindication, all patients underwent an MRI during
hospitalization and patients were classified according to
the Trial of ORG 10,172 in Acute Stroke Treatment
(TOAST) criteria [23]. The choice of antithrombotic
agents after MT was decided according to individual
cases.
In the CRS group, we additionally collected the loca-
tion and stage of cancer, presence of systemic metastasis,
pathologic type whether adenocarcinoma or not, and
serum D-dimer levels. Regarding the indicators of clin-
ical outcomes, mRS score at discharge, NIHSS score at
discharge, mRS score at 3 months, mortality during
hospitalization and after 3 months, and causes of mortal-
ity at 3 months were gathered. We defined unfavorable
outcome as a 3-month mRS score ≥ 3 [24].
Radiologic assessment
A single neurologist and a single radiologist, blinded to
the clinical information, independently analyzed the
angiographic data; the recanalization status was evalu-
ated according to the modified thrombolysis in cerebral
infarction (mTICI) scale through digital subtraction
angiography [25]. Successful recanalization was defined
as mTICI 2b or 3.
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Cerebral hemorrhage included any intracerebral or
subarachnoid hemorrhage found on the 24 h follow-up
imaging. All patients who received MT were followed up
immediately after 24 h by CT or MRI according to the
stroke management protocol of SNUH. Reported hem-
orrhages were categorized according to the Heidelberg
Bleeding Classification (HBC) [26].
Statistical analysis
Statistical analysis was performed using IBM SPSS ver-
sion 25 (IBM Corp., Armonk, NY, USA). Data were pre-
sented as means and medians with corresponding
standard deviations and interquartile ranges, respect-
ively. Univariate analyses (independent sample t test or
Mann-Whitney U test for continuous variables, and χ2
test or Fisher’s exact test for categorical variables) were
performed to compare demographics, vascular risk fac-
tors, laboratory findings, location of stroke onset, use of
rtPA, and occlusion site between groups. We also com-
pared radiological results such as reperfusion status and
presence of any cerebral hemorrhage. Multivariate
models were constructed to investigate what factors in-
dependently predicted unfavorable outcomes in the CRS
group after MT. A two-sided P value of < 0.05 was con-
sidered statistically significant.
Results
Baseline characteristics of the total study participants
A total of 341 participated in our study. Thirty-four
(9.9%) had CRS, while 307 (90.1%) had ischemic stroke
due to other mechanisms. The mean age of the patients
was 68.46 ± 13.2 years. Among the total 341 patients,
178 were male (52.2%). Age, sex, premorbid mRS scores,
vascular disease risk factors and baseline NIHSS scores
were not significantly different between the CRS and
control group, except for history of atrial fibrillation (0%
vs. 57.0%, p < 0.001). The levels of hemoglobin and
platelet count were significantly lower (10.8 ± 2.1 g/dℓ vs.
controls 13.1 ± 2.1 g/dℓ, 187.7 ± 105.9 × 103/μL vs. con-
trols 216.3 ± 72.3 × 103/μL, p < 0.001, p < 0.001, respect-
ively). However, leukocyte count and CRP levels were
significantly higher (10.7 ± 6.3 × 103/μL vs. controls 8.8 ±
3.5 × 103/μL, 6.3 ± 8.2 mg/dℓ vs. controls 1.5 ± 3.5 mg/dℓ,
p = 0.042, p < 0.001, respectively) in the CRS group. Fur-
thermore, in-hospital stroke was significantly more fre-
quent in the CRS group (32.4% vs. controls 7.8%, p <
0.001). There was no significant difference in the level of
total cholesterol, triglyceride, HDL-C, LDL-C, occlusion
site where MT was performed, and status of receiving
intravenous rtPA between the two groups (Table 1).
Comparison of the outcomes of MT between CRS and
control groups
There was no statistically significant difference in time
variables such as onset-to-puncture time and puncture-
to-reperfusion time between two groups. The rate of
successful recanalization was not significantly different
(76.5% vs. controls 87.6%, p = 0.103) yet any cerebral
hemorrhage was significantly more frequent in the CRS
group (41.2% vs. controls 23.8%, p = 0.037). Both, imme-
diate clinical outcomes as well as short-term outcomes
were all significantly unfavorable in the CRS group (me-
dian CRS group mRS score at discharge 5, interquartile
range (IQR) 3 to 5, controls median mRS at discharge 3,
IQR 1 to 5, p = 0.044; median CRS group mRS score at
3 months 4, IQR 2 to 5.25, controls median mRS at 3
month 3, IQR 1 to 4, p = 0.026). Mortality during the
hospitalization and at 3 months was significantly higher
(20.6% vs. controls 5.9%, p = 0.009 and 26.5% vs. con-
trols 6.8%, p < 0.001, respectively) in the CRS group.
However, most patients died because of the stroke itself
and the causes of mortality at 3 months were not signifi-
cantly different between two groups. (Table 2).
Baseline characteristics and outcomes according to
functional outcomes at 3 months after stroke of CRS
patients
Among a total of 34 patients, only 11 (32.4%) subjects
showed good functional outcome (mRS scores 0–2) at 3
months. In this group, the proportion of men was sig-
nificantly higher (81.8% vs. controls 34.7%, p = 0.026)
and exhibited significantly less stroke severity (median
baseline NIHSS score 9, IQR 7.5 to 13.5 vs. controls me-
dian baseline NIHSS score 20, IQR 17 to 25, p < 0.001).
Vascular risk factors, previous use of antithrombotic
agents, status of receiving rtPA and occluded site were
not significantly different between two groups. Onset-to-
puncture time, puncture-to-reperfusion time and the
rate of successful recanalization rate were not signifi-
cantly different. However, the group with favorable out-
come showed significantly less any cerebral hemorrhage
after MT (9.1% vs. unfavorable group 60.9%, p < 0.001).
There was no significant difference in cancer location
and type between the two groups. However, the cancer
stage was more aggravated, the systemic metastasis was
more prevalent (78.3% vs. favorable group 36.4%, p =
0.016) in the unfavorable group. Lastly, serum D-dimer
level were significantly elevated in the unfavorable group
(Unfavorable group D-dimer level median 16.95 mg/dL,
IQR 14.55 to 26.60 vs. favorable group D-dimer level
median 10.7 mg/dL, IQR 6.66 to 17.71 mg/dL, p = 0.028,
see Table 3).
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Factors associated with unfavorable outcome in CRS after
MT
In a univariate analysis of CRS patients, the following
factors were significantly associated with unfavorable
outcomes: higher initial NIHSS score, male gender,
higher serum D-dimer level, occlusion of the M2 seg-
ment of middle cerebral artery, presence of systemic
metastasis and any cerebral hemorrhage after endo-
vascular treatment. In a binary logistic regression ana-
lysis (adjusting for demographics and variables
achieving a p value of < 0.1 in the univariate
analyses), elevated serum D-dimer level and higher
baseline NIHSS score independently predict unfavor-
able outcome for CRS patients after MT (adjusted
odds ratio (aOR): 1.524, 95% confidence interval (CI):
1.043–2.226; aOR: 1.264, 95% CI: 1.010–1.582, re-
spectively, see Table 4).
Discussion
In this study, although the rate of successful recanaliza-
tion was not significantly different between the CRS and
control groups, the degree of functional recovery was
Table 1 Baseline characteristics of the total participants
Cancer-related stroke Control p
value
n (%) or mean ± SD or median (IQR) n (%) or mean ± SD or median (IQR)
Total 34 (100%) 307 (100%)
Age, years 64.5 ± 11.4 68.9 ± 14.0 0.124
Sex, male [n (%)] 17 (50%) 161 (52.4%) 0.921
Premorbid mRS score 0 (0–1.75) 0 (0–0) 0.294
Baseline NIHSS score 18 (11–23) 15 (8–19) 0.290
Comorbidities
Hypertension 22 (64.7%) 219 (71.3%) 0.768
Diabetes 14 (41.1%) 106 (34.5%) 0.621
Hyperlipidemia 9 (26.5%) 139 (45.3%) 0.328
Coronary artery disease 5 (14.7%) 59 (19.2%) 0.142
Prior stroke or TIA 6 (17.7%) 82 (26.7%) 0.306
Smoking 5 (14.7%) 92 (30.0%) 0.072
Atrial fibrillation 0 (0%) 175 (57.0%) < 0.001
Previous use of antithrombotics† 13 (38.2%) 98 (31.9%) 0.336
Laboratory findings
Hemoglobin, g/dℓ 10.8 ± 2.1 13.1 ± 2.1 < 0.001
White blood cells, 103/μL 10.7 ± 6.3 8.8 ± 3.5 0.042
Platelet counts, 103/μL 187.7 ± 105.9 216.3 ± 72.3 < 0.001
Prothrombin time, sec/INR 1.2 ± 0.2 1.1 ± 0.3 0.562
Total cholesterol, mg/dℓ 150.2 ± 47 160.2 ± 42.3 0.134
Triglyceride, mg/dℓ 110.4 ± 52.7 99.0 ± 53.5 0.172
HDL cholesterol, mg/dℓ 38.1 ± 17 47.2 ± 15.1 0.094
LDL cholesterol, mg/dℓ 92.1 ± 32 97.5 ± 37.5 0.328
C-reactive protein, mg/dℓ 6.3 ± 8.2 1.5 ± 3.5 < 0.001
In-hospital Stroke 11 (32.4%) 24 (7.8%) < 0.001
Occlusion site
Middle cerebral artery 24 (70.6%) 172 (56.0%) 0.143
M1 18 (52.9%) 118 (38.4%) 0.139
M2 6 (17.6%) 54 (17.6%) 0.993
Anterior cerebral artery 1 (2.9%) 16 (5.2%) 0.478
Posterior cerebral artery/Basilar artery 4 (11.8%) 54 (17.6%) 0.479
Internal carotid artery 5 (14.7%) 63 (20.5%) 0.504
Common carotid artery 0 (0%) 2 (0.6%) 0.998
Use of intravenous rtPA 9 (26.5%) 80 (26.1%) 0.959
Abbreviations: SD standard deviation, IQR interquartile range, mRS modified Rankin scale, NIHSS National institute of health stroke scale, TIA transient ischemic
attack, INR international normalized ratio, HDL High-density lipoprotein, LDL low-density lipoprotein, rtPA recombinant tissue plasminogen activator
†Antiplatelets and anticoagulation agents
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significantly worse in CRS than that of the control
group. These were similar to the findings of previous
studies conducted on the MT results of patients with ac-
tive cancer. Generally, recanalization rate was found to
be relatively high, but the degree of short-term func-
tional recovery was found to be poor, and a high mortal-
ity rate at 3 months was observed. (Table 5).
According to our analysis, most deaths within 3
months (77.8%) were related to cerebral infarction and
occurred during hospitalization. Similar to our results,
Lee et al. reported that most deaths are caused by the
ischemic stroke itself rather than the progression of can-
cer [12]. After stroke, anti-cancer therapy was usually
stopped until the stroke stabilized. Further, stroke affects
mortality in patients with active cancer by various ways
including the termination of malignancy treatment and
the worsening of general conditions. Moreover, Oki
et al. showed that 92% of patients with cancer-related
stroke died within 1 y after the stroke occurred [17]. In
cancer patients, thromboembolism and progression of
cancer are major causes of death. Taking all these results
into consideration, the cause of death within a short
Table 2 The results after mechanical thrombectomy of cancer-related stroke and controls
Cancer-related stroke Controls p
valuen (%) or mean ± SD or median (IQR) n (%) or mean ± SD or median (IQR)
Total 34 (100%) 307 (100%)
Time variable
Onset-to-puncture time, min 327.5 (170.25–507.5) 330 (185–602.5) 0.751
Puncture-to-reperfusion time, min 66.5 (42.5–90.5) 60 (41–90) 0.784
Radiological outcomes
Reperfusion status 0.758
mTICI 0, 1 2 (5.9%) 15 (4.9%)
mTICI 2a 5 (14.8%) 23 (7.5%)
mTICI 2b 14 (41.2%) 112 (36.5%)
mTICI 3 13 (38.2%) 157 (51.1%)
Successful recanalization 26 (76.5%) 269 (87.6%) 0.103
Any cerebral hemorrhage 14 (41.2%) 73 (23.8%) 0.037
HBC Class 1a 0 4
HBC Class 1b 2 21
HBC Class 1c 3 18
HBC Class 2 7 25
HBC Class 3a 0 0
HBC Class 3b 0 0
HBC Class 3c 2 5
HBC Class 3d 0 0
Craniectomy 3 (21.4%) 18 (24.6%) 0.452
Clinical outcomes
NIHSS score at discharge 13 (8–30) 5 (2–12.5) < 0.001
mRS score at discharge 5 (3–5) 3 (1–5) 0.044
mRS score at 3 months 4 (2–5.25) 3 (1–4) 0.026
Mortality during the hospitalization 7 (20.6%) 18 (5.9%) 0.009
Mortality at 3 months 9 (26.5%) 21 (6.8%) < 0.001
Causes of death at 3 months 0.687
Stroke 7 15
Sepsis 1 3
Progression of cancer 1 0
Others 0 3
Abbreviations: SD standard deviation, IQR interquartile range, min minutes, mTICI modified thrombolysis in cerebral infarction, HBC the Heidelberg Bleeding
Classification, mRS modified Rankin Scale, NIHSS National institute of health stroke scale
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Table 3 Baseline characteristics and outcomes according to functional outcomes at 3 months of cancer-related stroke
Characteristics Favorable outcome Unfavorable outcome p
value3-Month mRS score 0–2 3-Month mRS score 3–6
Total N = 11 N = 23
Age, year, median (IQR) 70 (57–73.50) 65 (59–72.50) 0.690
Male 9 (81.8%) 8 (34.7%) 0.026
Pre mRS score, median (IQR) 0 (0–0) 0 (0–2.5) 0.153
Initial NIHSS score, median (IQR) 9 (7.5–13.5) 20 (17–25) < 0.001
Vascular risk factors
Prior stroke or TIA 4 (36.3%) 2 (8.7%) 0.070
Coronary artery disease 1 (9.1%) 4 (17.4%) 0.507
Hypertension 7 (63.6%) 15 (65.2%) 0.928
Diabetes mellitus 4 (36.4%) 8 (34.8%) 0.928
Dyslipidemia 4 (36.4%) 9 (39.1%) 0.878
Smoking 3 (27.3%) 2 (8.7%) 0.300
Previous use of antithrombotics† 4 (30.8%) 9 (39.1%) 0.876
Administration of IV-rtPA 1 (9.1%) 8 (34.8%) 0.214
Occlusion site 0.861
Middle cerebral artery, M1 5 (45.4%) 13 (56.5%)
Middle cerebral artery, M2 2 (18.2%) 4 (17.4%)
Internal carotid artery 3 (27.3%) 2 (8.7%)
Anterior cerebral artery 0 (0%) 1 (4.3%)
Posterior cerebral artery/Basilar artery 1 (9.1%) 3 (13.1%)
In-Hospital Stroke 4 (36.4%) 7 (30.4%) 0.731
Time variables
Onset-to-puncture time, min, SD 471 (290.24) 364.39 (224.31) 0.612
Puncture-to-reperfusion time, min, SD 74.45 (27.48) 80.17 (46.13) 0.856
Radiologic Outcomes
Recanalization status 0.160
mTICI 3, 2b 11 (100%) 16 (69.6%)
mTICI 2a 0 (0%) 5 (21.7%)
mTICI 1, 0 0 (0%) 2 (8.7%)
Any cerebral hemorrhage 1 (9.1%) 13 (56.5%) < 0.001
Cancer by location 0.510
Pancreatic cancer 2 (18.2%) 7 (30.4%)
Lung cancer 4 (36.4%) 3 (13.0%)
Bile duct cancer 2 (18.2%) 3 (13.0%)
Liver cancer 1 (9.1%) 2 (8.7%)
Gastric cancer 0 (0%) 2 (8.7%)
Colon cancer 1 (9.1%) 2 (8.7%)
Ovarian cancer 1 (9.1%) 2 (8.7%)
Breast cancer 0 (0%) 2 (8.7%)
Cancer stage 0.018
III 7 (63.6%) 5 (21.7%)
IV 4 (36.4%) 18 (78.3%)
Cancer type 0.280
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period after stroke in the CRS group is often the stroke
itself, and the causes of long-term mortality might be
the discontinuation of anti-cancer therapy after stroke
and the general deconditioning. Therefore, it might be
necessary to actively perform MT in a more selected
group to achieve functional recovery in CRS, and to con-
tinue anti-cancer therapy. In addition, in some cases,
MT in CRS could enable an improved quality of life.
Further research on a larger scale of long-term prognosis
of CRS after MT is needed.
In the comparison of baseline characteristics between
the CRS group and the control, hemoglobin level was
significantly lower and leukocyte count was significantly
elevated in the CRS group. Inadequate hemoglobin level
and elevated leukocyte count is frequently associated
with cancer and cancer-related coagulopathy [27–29].
These factors are also associated with unfavorable prog-
nosis after stroke [30]. Furthermore, CRP levels were sig-
nificantly higher in the CRS group than the control
group. As an inflammatory marker, higher CRP may re-
flect acute inflammation which trigger for thrombo-
embolism, or CRP itself is related to coagulation
pathway and therefore may activate the cancer-specific
prothrombotic mechanisms [31, 32]. In previous studies,
higher circulating levels of CRP are associated with un-
favorable outcomes in patients with solid malignancies
[33]. Distinctively, CRS is significantly more occurred
during hospitalization. This may suggest the possibility
that anti-cancer therapies such as chemotherapy and
radiotherapy, and various invasive procedures may be re-
lated to pathogenesis of CRS [34]. Or, according to the
reason for the patients’ hospitalization, infection or in-
flammation may brought about cancer-related coagulop-
athy. Further research about factors associated with CRS
during hospitalization is needed.
Interestingly, even though there is no significant differ-
ence in the baseline NIHSS scores, rate of successful re-
canalization, time variables such as onset-to-puncture
time and puncture-to-reperfusion time, and use of rtPA
between CRS and control groups, any cerebral
hemorrhage after MT was significantly higher in the
CRS group. Whether post-procedural hemorrhage occur
more frequently in active cancer patients is still debat-
able [35, 36]. However, in the case of cancer-related co-
agulopathy such as disseminated intravascular
coagulation, activation of coagulation may lead to ex-
haustion of platelets and coagulation factors, and even-
tually bleeding [37]. Also, the platelet count of CRS
group is significantly lower than control in our results.
In addition, the risk of cerebral hemorrhage may have
increased if liver function associated with synthesis of
blood coagulation factors is affected by primary or
Table 3 Baseline characteristics and outcomes according to functional outcomes at 3 months of cancer-related stroke (Continued)
Characteristics Favorable outcome Unfavorable outcome p
value3-Month mRS score 0–2 3-Month mRS score 3–6
Adenocarcinoma 11(100%) 19 (82.6%)
Others 0 (0%) 4(17.4%)
Systemic metastasis 4 (36.4%) 18 (78.3%) 0.016
D-dimer, median (IQR) 10.7 (6.66–17.71) 16.95 (14.55–26.60) 0.028
Abbreviations: mRS modified Rankin scale, IQR interquartile range, NIHSS National institute of health stroke scale, TIA transient ischemic attack, IV intravenous, rtPA
recombinant tissue plasminogen activator, mTICI modified thrombolysis in cerebral infarction
†Antiplatelets and anticoagulation agents
Table 4 Factors associated with unfavorable outcome (3-month mRS≥ 3) in cancer-related stroke after mechanical thrombectomy
Covariate Crude OR (95% Cl) p value Adjusted OR*(95% Cl) p value
Initial NIHSS score 1.321 (1.104–1.580) 0.002 1.264 (1.010–1.582) 0.041
Pre-stroke mRS score 2.418 (0.916–6.388) 0.075 3.207 (0.293–35.134) 0.340
Prior stroke or TIA 0.167(0.025–1.115) 0.065 2.380 (0.007–14.578) 0.442
Sex (Men) 0.119 (0.020–0.686) 0.017 0.771 (0.004–5.983) 0.575
Occlusion of MCA, M2 0.167 (0.025–1.115) 0.065 0.077 (0.001–1.967) 0.442
Occlusion of ICA 0.080 (0.008–0.835) 0.035 0.557 (0.006–4.924) 0.798
D-Dimer 1.617 (1.159–2.255) 0.049 1.524 (1.043–2.226) 0.029
Any cerebral hemorrhage 15.556 (1.690–143.174) 0.015 6.676 (0.052–18.481) 0.443
Systemic metastasis 6.300 (1.300–30.533) 0.022 1.291(0.847–1.967) 0.118
* Adjusted for baseline NIHSS scores, Pre-stroke mRS, Prior history of stroke or TIA, Sex, Occlusion of M2 segment of MCA and ICA, presence of any cerebral
hemorrhage and systemic metastasis
Abbreviations: OR odds ratio, CI confidence interval, NIHSS National institute of health stroke scale, TIA Transient ischemia attack, mRS modified Rankin scale, MCA
Middle cererbral artery, ICA internal carotid artery
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metastatic cancer. Immediate and short-term clinical
outcomes are all significantly unfavorable in CRS group
than controls. This may be due to clinical course of can-
cer itself, or it could be explained by that it was because
of cerebral hemorrhage after MT interrupted appropri-
ate management of ischemic stroke.
In the CRS group, the location of cancer varied, how-
ever mainly pancreas, lung, and bile ducts. The type of
cancer cell was overwhelmingly adenocarcinoma. All
CRS patients had advanced-stage III or more. These
findings are all consistent with the results of previous
studies about CRS [34]. Bang. Et al identified that circu-
lating cancer-cell extracellular vesicles were higher in
lung adenocarcinoma and had a direct role in blood
clotting [2]. Understanding the features and further re-
search on the pathologic mechanism of CRS is necessary
for development of its proper treatment.
Another notable finding of this study was that elevated
serum D-dimer level and higher baseline NIHSS scores
independently associated with unfavorable outcomes in
CRS after MT. As nonspecific biomarker of hypercoagu-
lability, high D-dimer levels have been known to be re-
lated to poor prognosis in CRS [38, 39]. They are also
associated with disturbing recanalization and increasing
reperfusion injury [40]. Thus, elevated D-dimer levels
may also explain the high incidence of intracerebral
hemorrhage after MT in CRS. In previous studies, base-
line NIHSS scores have been shown to be associated
with post-MT prognosis in patients with AIS [41–43].
Therefore, thrombectomy for CRS patients, especially in
a case of patients with elevated serum D-dimer level and
more severe stroke, needs more judicious decision and
great care should be taken to prevent post-procedural
cerebral hemorrhage.
The strength of this study is that we analyzed the inde-
pendently associated factors of unfavorable outcome in
patients with CRS after MT. To the best of our know-
ledge, this is the first study that investigates the predic-
tors of functional outcome within CRS patients after
MT. As an emerging subtype of ischemic stroke, CRS is
associated with cancer-related coagulopathy and its rates
are expected to increase in future. This will encourage
further research to take place to better understand and
treat the disease.
This study has several limitations. First, it is a retro-
spective study with a relatively small number of patients
from a single center. Larger sample study is needed to
elucidate the effectiveness of MT in patients with CRS.
Second, a detailed analysis of treatment status of cancer
was not sufficiently performed. It was difficult to incorp-
orate this due to the small sample size. Hence, only the
location, stage, presence of metastasis and pathologic
features of adenocarcinoma were included. Third,
among the control group, patients with inactive cancer
were not excluded. The effect that inactive cancer might
have on stroke occurrence and prognosis is not clear.
However, cancer-related coagulopathy is known to have
a strong correlation with cancer activity, and the histo-
logical features of thrombi are also known to be different
between stroke patients with active cancer and inactive
cancer [44]. Therefore, we believe that there is little pos-
sibility that inactive cancer affected the occurrence and
prognosis of the CRS that we focused on. Lastly, al-
though there was no significant difference in the rate of
MT performed in the M2 segment between CRS and
control groups, it is likely that MT was less frequently
performed in the CRS group than in the control group.
Due to the medical condition of CRS patients, there are
Table 5 Comparison of the results between present and earlier studies














Number of cases 26 19 27 24 62 12 34
Age (years, mean/median) 63 (median) 69 (median) 69 (mean) 69 (mean) 70 (median) 64 (mean) 64.5 (mean)
Male, sex 18 (69.2%) 9 (47.4%) 20 (74.1%) 8 (33.3%) 29 (46.8%) 5 (41.7%) 17 (50%)
Baseline NIHSS (mean/median) 14 (median) 16 (median) 11 (median) 14.2 (mean) 15 (median) 17.2 (mean) 18 (median)
Cancer stage IV (%) N/A 89.5% 29.6% 41.7% 69.4% 58.0% 64.7%
Prestroke mRS ≤ 2 N/A N/A 100.0% 95.8% N/A 83.0% 88.2%
IV-rtPA 19.2% 15.8% 63.0% 45.8% 14.5% 33.0% 26.5%




30 (median) N/A 52.9 (mean) 29 (median) 70 (mean) 66.5
(median)
Succesful reperfusion (mTICI 2b or 3) 88.5% 63.2% 85.2% 76.9% 75.8% 83.0% 76.5%
mRS 0–2 at 3 months 23.1% 15.8% 37.0% 41.7% 17.7% 25.0% 32.0%
Mortality at 3 months 30.8% 63.2% 33.3% 29.1% 48.4% 50.0% 26.5%
Mortality at 12 months N/A N/A N/A N/A N/A 92.0% N/A
Abbreviations: NIHSS National Institutes of Health Stroke Scale score, rtPA recombinant tissue plasminogen activator; mTICI modified thrombolysis in cerebral
infarction, mRS modified Rankin scale, N/A not available
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cases in which MT cannot be performed in consider-
ation of risks and benefits. However, this study lacks
consideration for these cases, including only the cases
where MT was performed. These limitations should be
considered while interpreting the study results.
Conclusion
In conclusion, successful recanalization rate was similar
in both CRS and control groups with no differences in
baseline NIHSS scores and time variables. Thus, for re-
vascularization, MT is an appropriate therapeutic treat-
ment for CRS. However, post procedural intracerebral
hemorrhage were more frequent and overall functional
outcomes are unfavorable in the CRS group. Careful
consideration of the D-dimer level and the baseline
stroke severity is necessary when considering MT for pa-
tients with CRS. Further research is warranted to evalu-
ate the significance of these predictors.
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C: Low-density lipoprotein cholesterol; CRP: C-reactive protein; SNUH: Seoul
National University Hospital; MCA: Middle cerebral artery; ICA: Internal carotid
artery; PCA: Posterior cerebral artery; BA: Basilar artery; CT: Computed
tomography; MRI: Magnetic resonance image; mRS: Modified Rankin scale;
TOAST: Trial of ORG 10,172 in Acute Stroke Treatment; mTICI: Modified
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